As of July 2026, the rapid rise of GLP-1 medications continues to be a dominant topic in public health and the medical community, particularly concerning their impact on the persistent U.S. obesity epidemic. With ongoing discussions about accessibility, cost, and long-term effects, understanding the current adoption rates of these drugs and their correlation with national obesity statistics is more crucial than ever for healthcare professionals, policymakers, and the public.
This chart, titled "GLP-1 Medication Use and U.S. Obesity Rate: 2022/2024 vs. July 2026," provides a vital look at these evolving trends. It illustrates the percentage of U.S. adults who have ever used GLP-1 medications for weight loss, alongside those currently on the drugs, and compares these figures with the overall U.S. obesity rate. By presenting data from 2024 against the most recent findings from early July 2026, the chart offers key insights into the recent trajectory of GLP-1 adoption and its potential influence on national health outcomes.
For context, the chart uses 2024 data as the closest available prior point for GLP-1 usage, as 2022 figures were unavailable. The up-to-date July 2026 statistics are based on a recent Gallup poll, providing a timely and relevant comparison. This analysis helps to frame the ongoing discussion about how these groundbreaking medications are shaping the health landscape across the United States.